Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.
CYP2B6
HIV
HIV drug resistance
Post-partum
Pregnancy
Single nucleotide polymorphisms
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
31 03 2023
31 03 2023
Historique:
received:
03
01
2023
accepted:
24
03
2023
medline:
4
4
2023
entrez:
2
4
2023
pubmed:
3
4
2023
Statut:
epublish
Résumé
We investigated the association between CYP2B6 polymorphisms and efavirenz drug resistance among women living with HIV who started on antiretroviral therapy during pregnancy and with high viremia during post-partum. This was a cross-sectional study of women with viral loads greater than 1000 copies/ml who were at least 6 weeks postpartum. Sanger sequencing was used to detect resistant mutations, as well as host genotyping, and efavirenz resistance was compared among the metabolizer genotypes. Over the course of one year (July 2017-July 2018), 322 women were screened, with 110 (34.2%) having viral loads of 1000 copies/ml and 62 having whole blood available for genotyping. Fifty-nine of these women had both viral resistance and human host genotypic results. Efavirenz resistance according to metabolizer genotype was; 47% in slow, 34% in extensive and 28% in intermediate metabolizers, but the difference was not statistically significant due to the small sample size. There was no statistically significant difference in EFV resistance between EFV metabolizer genotypes in women who started antiretroviral therapy during pregnancy and had high viremia in the postpartum period. However, a numerical trend was discovered, which calls for confirmation in a large, well-designed, statistically powered study.
Sections du résumé
BACKGROUND
We investigated the association between CYP2B6 polymorphisms and efavirenz drug resistance among women living with HIV who started on antiretroviral therapy during pregnancy and with high viremia during post-partum.
METHODS
This was a cross-sectional study of women with viral loads greater than 1000 copies/ml who were at least 6 weeks postpartum. Sanger sequencing was used to detect resistant mutations, as well as host genotyping, and efavirenz resistance was compared among the metabolizer genotypes.
RESULTS
Over the course of one year (July 2017-July 2018), 322 women were screened, with 110 (34.2%) having viral loads of 1000 copies/ml and 62 having whole blood available for genotyping. Fifty-nine of these women had both viral resistance and human host genotypic results. Efavirenz resistance according to metabolizer genotype was; 47% in slow, 34% in extensive and 28% in intermediate metabolizers, but the difference was not statistically significant due to the small sample size.
CONCLUSIONS
There was no statistically significant difference in EFV resistance between EFV metabolizer genotypes in women who started antiretroviral therapy during pregnancy and had high viremia in the postpartum period. However, a numerical trend was discovered, which calls for confirmation in a large, well-designed, statistically powered study.
Identifiants
pubmed: 37004096
doi: 10.1186/s12981-023-00514-2
pii: 10.1186/s12981-023-00514-2
pmc: PMC10064798
doi:
Substances chimiques
Cytochrome P-450 CYP2B6
EC 1.14.14.1
Anti-HIV Agents
0
efavirenz
JE6H2O27P8
Benzoxazines
0
CYP2B6 protein, human
EC 1.14.14.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Pharmacol Exp Ther. 2006 Jul;318(1):345-51
pubmed: 16611850
Pharmacogenet Genomics. 2016 Aug;26(8):381-9
pubmed: 27195527
AIDS. 2004 Dec 3;18(18):2391-400
pubmed: 15622315
Intervirology. 2012;55(2):98-101
pubmed: 22286876
BMC Infect Dis. 2018 Apr 13;18(1):175
pubmed: 29653510
AIDS. 2017 Jul 17;31(11):1593-1602
pubmed: 28463877
J Antimicrob Chemother. 2008 Apr;61(4):914-8
pubmed: 18281305
AIDS. 2001 Jan 5;15(1):71-5
pubmed: 11192870
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S149-S155
pubmed: 28498184
AIDS. 2020 Mar 15;34(4):589-597
pubmed: 31821189
BMC Infect Dis. 2013 Jun 04;13:261
pubmed: 23734829
PLoS One. 2021 May 21;16(5):e0251413
pubmed: 34019568
Infection. 2014 Jun;42(3):469-74
pubmed: 24293076
BMC Infect Dis. 2015 Apr 08;15:175
pubmed: 25886277
Pharmgenomics Pers Med. 2021 Mar 16;14:335-347
pubmed: 33758532